ISTANBUL -- Researchers in Turkey on Wednesday reported an efficacy rate of 83.5% for the coronavirus vaccine developed by Chinese company Sinovac Biotech based on final Phase 3 clinical trial results there, down from 91.25% announced in late December from interim results.
Professor Serhat Unal, a member of Turkey's COVID-19 advisory board and a leader of the clinical trial, told Nikkei Asia that data was used from 10,030 volunteers in the study out of 10,216 participants. The interim results covered only 1,322 volunteers. The final rate of 83.5% is based on 41 infections, in which 32 of the individuals had received a placebo.
